Evidence map›Paper›PMID 33268410›Full record

ArticleBMJ open2020

Exclusion of enrolled participants in randomised controlled trials: what to do with ineligible participants?

Andrea M Rehman, Rashida Ferrand, Elizabeth Allen, Victoria Simms, Grace McHugh, Helen Anne Weiss

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02426112 (Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02426112 phase3completednot on this map

Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2016 to 2019Enrolled347ConditionsChronic Lung Disease, HIV InfectionArmsAzithromycin, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors.The New England journal of medicine · 2023
    Trial
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Andrea M RehmanMRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK andrea.rehman@lshtm.ac.uk.ORCID 0000-0001-9967-5822
Rashida FerrandDepartment of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Elizabeth AllenDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Victoria SimmsMRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.
Grace McHughBiomedical Research and Training Institute, Harare, Zimbabwe.
Helen Anne WeissMRC International Statistics & Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0003-3547-7936
London School of Hygiene & Tropical Medicine · GBBiomedical Research and Training Institute · ZW

Funding

Medical Research Council MR/R010161/1Wellcome TrustWellcome Trust 206316/Z/17/Z
6 · The paper itself

Abstract

objectivePost-randomisation exclusions in randomised controlled trials are common and may include participants identified as not meeting trial eligibility criteria after randomisation. We report how a decision might be reached and reported on, to include or exclude these participants. We illustrate using a motivating scenario from the BREATHE trial (Trial registration ClinicalTrials.gov, NCT02426112) evaluating azithromycin for the treatment of chronic lung disease in people aged 6-19 years with HIV in Zimbabwe and Malawi. KEY POINTS: Including all enrolled and randomised participants in the primary analysis of a trial ensures an unbiased estimate of the intervention effect using intention-to-treat principles, and minimises the effects of confounding through balanced allocation to trial arm. Ineligible participants are sometimes enrolled, due to measurement or human error. Of 347 participants enrolled into the BREATHE trial, 11 (3.2%) were subsequently found to be ineligible based on lung function criteria. We assumed no safety risk of azithromycin treatment; their inclusion in the trial and subsequent analysis of the intervention effect therefore mirrors clinical practice. Senior trial investigators considered diurnal variations in the measurement of lung function, advantages of retaining a higher sample size and advice from the Data Safety and Monitoring Board and Trial Steering Committee, and decided to include these participants in primary analysis. We planned and reported analyses including and excluding these participants, and in our case the interpretation of treatment effect was consistent.

conclusionThe decision, by senior investigators, on whether to exclude enrolled participants, should reflect issues of safety, treatment efficacy, statistical power and measurement error. As long as decisions are made prior to finalising the statistical analysis plan for the trial, the risk of exclusions creating bias should be minimal. The decision taken should be transparently reported and a sensitivity analysis can present the opposite decision.

Indexed as

Patient SelectionRandomized Controlled Trials as TopicAdolescentAdultChildHumansMalawiTreatment OutcomeYoung AdultZimbabweeducation & training (see medical education & training)paediatric thoracic medicinestatistics & research methods

Identifiers

PMID33268410
PMCPMC7713189
OpenAlexW3109146887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.